



# BRINGING STAKEHOLDERS TOGETHER

**Gabriel Baertschi**

**CEO Grünenthal**

**EFPIA board member**


**Malta, June 9th 2017**



# PAIN – IS A DAY-BY-DAY REALITY FOR MILLIONS



# THE SOCIETAL IMPACT OF PAIN IS A SEVERE PROBLEM



<sup>1</sup> Langley P.C.: The prevalence, correlates and treatment of pain in the European Union. *CMRO*. 2011;463-480

<sup>2</sup> Wiffen P: Pain – there is a lot of it. *Eur J Hosp Pharm*. 2013; 20:1

<sup>2</sup> Benhamou D et al.: Did you know that often pain is not assessed and recorded? Approximately 34% of physicians say that post-operative pain is not assessed in their institution. *Pain*. 2008; 136:134-41

# PAIN: A PROBLEM FOR HEALTHCARE SYSTEMS, ECONOMIES AND SOCIETY



**153 Million**

People suffer from migraine or headaches



**200 Million**

People suffer from musculoskeletal disorders



**100 Million**

People experience chronic pain



Chronic pain causes almost **50%** of all absences from work

2-3 % GDP across the EU = €294 ...  
441 billions in 2016

# BRINGING ALL STAKEHOLDERS TOGETHER



# THE INNOVATIVE MEDICINES INITIATIVE (IMI) IS THE LARGEST PUBLIC-PRIVATE PARTNERSHIP FOR HEALTH RESEARCH WORLDWIDE



IMI is working to improve health by speeding up the development of, and patient access to, the next generation of medicines, particularly in areas of unmet medical and social need.



**PARTNERSHIP**  
2014 - 2024



# THE IMI2 PAIN GROUP – TO DRIVE SOLUTIONS IN PAIN



- Unites European pharmaceutical companies dedicated to better understand, treat and manage pain
- Enables cooperation with the best skilled non-EFPIA consortia
- 1st April 2017: first collaborative project with renowned public
- Project aspiration: increase knowledge of pain targets and pathways, and generate predictive approaches for discovery of new pain treatments






# OUR SCIENTISTS HAVE IDENTIFIED A PAIN LANDSCAPE



## Landscape

ACUTE PAIN	
1	BREAKTHROUGH PAIN
2	SICKLE CELL
NOICEPTIVE PAIN	
3	RAYNAUD
4	FYBROMYALGIA DISEASE
5	POST-TRAUMATIC STRESS DISORDER
6	CHEMOTHERAPY INDUCED ORAL MUCOSITIS
7	VASCULAR ULCERS
8	CLUSTER HEADACHE
9	LUPUS ERYTHEMATOSUS
10	VISCERAL CANCER PAIN
11	EHLERS-DANLOS
12	SCLERODERMA
13	BEHCET'S DISEASE
14	PYODERMA GANGRENOSUM
15	PEMPHIGUS
PERIPHERAL NEUROPATHIC PAIN	
16	POST-THORACOTOMY PERIPHERAL NEUROPATHY
17	CHARCOT NEUROARTHROPATHY
18	HIV PERIPHERAL NEUROPATHY
19	CRPS
20	POST-MASTECTOMY PERIPHERAL NEUROPATHY
21	TRIGEMINAL NEURALGIA
22	ERYTHROMELALGIA
23	FABRY DISEASE
CENTRAL NEUROPATHIC PAIN	
24	ALZHEIMER'S DISEASE PAIN
25	PARKINSON'S DISEASE PAIN
26	MULTIPLE SCLEROSIS PAIN
27	SPINAL CORD INJURY PAIN
28	POST-STROKE PAIN
MIXED BACK PAIN	
29	DISC DEGENERATION/RADICULOPATHY
30	FAILED BACK SURGERY SYNDROME
VISCERAL PAIN	
31	NON CARDIAC CHEST PAIN
32	IRRITABLE BOWEL SYNDROME
33	ENDOMETRIOSIS
34	VULVODYNIA
35	BLADDER PAIN SYNDROME
36	INFLAMMATORY BOWEL DISEASE REMISSION
37	BURNING MOUTH SYNDROME
38	CHRONIC PANCREATITIS

## Prevalences





# PROMISING CANDIDATES WITHIN THE GRÜNENTHAL PIPELINE




## Bisphosphonates

**CRPS (Chronic Regional Pain Syndrome)** extremely painful disease without approved therapy

**Niche indication** (100-200k patients in the US) – **up to USD 50k treatment cost per patient**


**Neridronate** achieved breakthrough designation status



## GRT-6010

First NOP Agonist - **high unmet need area** with new mode of action

**Three niche indications**




## Cav2.2.

An **oral, non-scheduled and non-opioid analgesic** suitable for **spinal cord injury and lumbo-sacral radiculopathy pain**

**Improved therapeutic window** through unique state-dependent blocking mode of action

# PATIENT ENGAGEMENT – EARLY RESEARCH AND DEVELOPMENT




# THE SOCIETAL IMPACT OF PAIN

To ensure access to adequate pain treatment for all citizens, addressing the societal impact of pain, we need to work together uniting all organisations and societies advocating better pain care to jointly address, define and foster pain policies



# THE SOCIETAL IMPACT OF PAIN 2017 – WHO IS HERE?



- > 330 registered participants
- 29 nationalities
- 250 organisations
- > 300 endorsing organisations
- >150 faculty members

# THANK YOU



MALTA EU 2017

